Please assess the completion status of the following clinical trial:

Trial Title: Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Male or female patient receiving insulin for the treatment of documented diagnosis of Type 1 Diabetes Mellitus (T1DM) for at least 1 year at the time of Visit 1~* Fasting C-peptide value of \< 0.7 ng/mL (0.23 nmol/L) at Visit 2 measured by the central laboratory~* Use of, and be willing, based on the Investigator's judgement, to continue throughout the duration of the trial, either:~  * Multiple Daily Injections (MDI) of insulin consisting of at least one basal insulin injection and at least three daily bolus injections OR~ * Continuous Subcutaneous Insulin Infusion (CSII) of any insulin type, with at least 5 months experience of using CSII prior to Visit 1~* HbA1c \>/= 7.5% and \</= 10.0% at Visit 5 measured by the central laboratory~* Age \>/= 18 years at Visit 1~Additional inclusion criteria may apply~Exclusion criteria:~* History of Type 2 Diabetes Mellitus (T2DM), maturity onset diabetes of the young (MODY), pancreatic surgery or chronic pancreatitis~* Pancreas, pancreatic islet cells or renal transplant recipient~* T1DM treatment with any other antihyperglycaemic drug (e.g. metformin, alpha-glucosidase inhibitors, Glucagon-like-peptide 1 (GLP-1) analogues, Sodium-Glucose Co-Transporter (SGLT-2) inhibitors, pramlintide, inhaled insulin, pre-mixed insulins etc.) except subcutaneous basal and bolus insulin within 3 months prior to Visit 1~* Occurrence of severe hypoglycaemia involving coma/unconsciousness and/or seizure that required hospitalisation or hypoglycaemia-related treatment by an emergency physician or paramedic within 3 months prior to Visit 1 and until randomisation~* Occurence of Diabetic Ketoacidosis (DKA) within 3 months prior to Visit 1 and until randomisation~Additional exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empagliflozin low dose (Type: EXPERIMENTAL): Empagliflozin tablets once daily
- Empagliflozin high dose (Type: EXPERIMENTAL): Empagliflozin tablets once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets matching empagliflozin once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).